Moperone information

Moperone
Clinical data
Trade names	Luvatren (discontinued)
ATC code	N05AD04 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances);
Identifiers
	IUPAC name 1-(4-fluorophenyl)-4-[4-hydroxy-4-(4-methylphenyl)piperidin-1-yl]butan-1-one;
CAS Number	1050-79-9;
PubChem CID	4249;
DrugBank	DB13554;
ChemSpider	4100;
UNII	OU730881W5;
KEGG	D02623;
CompTox Dashboard (EPA)	DTXSID6049062 ;
ECHA InfoCard	100.012.625
Chemical and physical data
Formula	C22H26FNO2
Molar mass	355.453 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1;
	InChI InChI=1S/C22H26FNO2/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18/h4-11,26H,2-3,12-16H2,1H3; Key:AGAHNABIDCTLHW-UHFFFAOYSA-N;

Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class^[2] which is marketed in Japan for the treatment of schizophrenia. It is an antagonist for the D₂ (K_i 0.7–1.9 nM), D₃ (K_i 0.1–1 nM), and 5-HT_2A (K_i 52 nM) receptors. It also has a high binding affinity for the sigma receptors.^[3]^[4]

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Gross H, Kaltenbäck E (1969). "The clinical position of moperone among the butyrophenones". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry. 23 (1): 4–9. doi:10.3109/08039486909132154. PMID 5354545.
^ Miyamoto S (2010). "Moperone". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 798. doi:10.1007/978-3-540-68706-1_1838. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
^ Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 21 March 2022.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] Gross H, Kaltenbäck E (1969). "The clinical position of moperone among the butyrophenones". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry. 23 (1): 4–9. doi:10.3109/08039486909132154. PMID 5354545.

[:0-3] Miyamoto S (2010). "Moperone". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 798. doi:10.1007/978-3-540-68706-1_1838. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.

[PDSP-4] Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 21 March 2022.

Moperone information

and 25 Related for: Moperone information

Moperone

Brazilian Controlled Drugs and Substances Act

Ketamine

LSD

Psychiatry

Phencyclidine

Domperidone

Buspirone

Levosulpiride

Amitriptyline

Promethazine

Haloperidol

Quetiapine

Salvia divinorum

Aripiprazole

Phenylalanine

ATC code N05

Metoclopramide

Risperidone

List of antipsychotics

Hydroxyzine

Bromocriptine

Olanzapine

Doxepin

Itopride